TRAF6 Blocking Peptide for STJ503382 is synthetically produced from the sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide corresponding to unique amino acid sequence on TRAF6 protein.
Specificity
This blocking peptide is recommended for use in combination with TRAF6 antibody, STJ503382
Additional Info
Tissue Specificity
Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
Post Translational Modifications
Sumoylated on Lys-124, Lys-142 and Lys-453 with SUMO1. Polyubiquitinated on Lys-124 by TRAF3IP2.after cell stimulation with IL17A. Polyubiquitinated on Lys-124.after cell stimulation with IL1B or TGFB. This ligand-induced cell stimulation leads to dimerization/oligomerization of TRAF6 molecules, followed by auto-ubiquitination which involves UBE2N and UBE2V1 and leads to TRAF6 activation. This 'Lys-63' site-specific poly-ubiquitination appears to be associated with the activation of signaling molecules. Endogenous autoubiquitination occurs only for the cytoplasmic form. Deubiquitinated by USP10 in a TANK-dependent manner, leading to the negative regulation of NF-kappaB signaling upon DNA damage. LRRC19 induces 'Lys-63' ubiquitination. Ubiquitinated at Lys-319 by the SCF(FBXL2) complex, leading to its degradation by the proteasome. (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1 on both 'Lys-48' and 'Lys-63'-linked ubiquitin chains.leading to NF-kappa-B signaling inhibition.
Function
E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as ECSIT, IKBKG, IRAK1, AKT1 and AKT2. Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation. Leads to the activation of NF-kappa-B and JUN. Seems to also play a role in dendritic cells (DCs) maturation and/or activation. Represses c-Myb-mediated transactivation, in B-lymphocytes. Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor. Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation. Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. Participates also in the TCR signaling by ubiquitinating LAT.
Peptide Name
Tnf Receptor-Associated Factor 6E3 Ubiquitin-Protein Ligase Traf6Interleukin-1 Signal TransducerRing Finger Protein 85Ring-Type E3 Ubiquitin Transferase Traf6
CytoplasmCell CortexNucleusLipid DropletFound In The Nuclei Of Some Aggressive B-Cell Lymphoma Cell Lines As Well As In The Nuclei Of Both Resting And Activated T- And B-LymphocytesFound In Punctate Nuclear Body Protein ComplexesUbiquitination May Occur In The Cytoplasm And Sumoylation In The NucleusRsad2/Viperin Recruits It To The Lipid Droplet
Alternative Peptide Names
Tnf Receptor-Associated Factor 6 proteinE3 Ubiquitin-Protein Ligase Traf6 proteinInterleukin-1 Signal Transducer proteinRing Finger Protein 85 proteinRing-Type E3 Ubiquitin Transferase Traf6 proteinTRAF6 proteinRNF85 protein
